Wang Y, Bendre S, Krauklis S, Steelman A, Nelson E
Endocrinology. 2025; 166(4).
PMID: 39951497
PMC: 11878532.
DOI: 10.1210/endocr/bqaf031.
Stolz V, de Freitas E Silva R, Rica R, Zhu C, Preglej T, Hamminger P
Elife. 2024; 13.
PMID: 39466314
PMC: 11517256.
DOI: 10.7554/eLife.78738.
Ramalingam P, Elangovan S, Mekala J, Arumugam S
Front Cell Dev Biol. 2024; 12:1386102.
PMID: 38550382
PMC: 10972936.
DOI: 10.3389/fcell.2024.1386102.
Song X, Wu W, Warner M, Gustafsson J
Biomedicines. 2022; 10(9).
PMID: 36140266
PMC: 9496004.
DOI: 10.3390/biomedicines10092165.
She J, Gu T, Pang X, Liu Y, Tang L, Zhou X
Front Pharmacol. 2022; 12:772435.
PMID: 35069197
PMC: 8766425.
DOI: 10.3389/fphar.2021.772435.
Characterization and prognostic value of LXR splice variants in triple-negative breast cancer.
Lianto P, Hutchinson S, Moore J, Hughes T, Thorne J
iScience. 2021; 24(10):103212.
PMID: 34755086
PMC: 8560626.
DOI: 10.1016/j.isci.2021.103212.
Liver X receptors and liver physiology.
Russo-Savage L, Schulman I
Biochim Biophys Acta Mol Basis Dis. 2021; 1867(6):166121.
PMID: 33713792
PMC: 9242550.
DOI: 10.1016/j.bbadis.2021.166121.
Differential Role of Liver X Receptor (LXR) and LXR in the Regulation of UDP-Glucuronosyltransferase 1A1 in Humanized Mice.
Hansmann E, Mennillo E, Yoda E, Verreault M, Barbier O, Chen S
Drug Metab Dispos. 2020; 48(4):255-263.
PMID: 31980500
PMC: 7065491.
DOI: 10.1124/dmd.119.090068.
Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease.
Sengupta M, Griffett K, Flaveny C, Burris T
ACS Pharmacol Transl Sci. 2019; 1(1):50-60.
PMID: 31696159
PMC: 6834356.
DOI: 10.1021/acsptsci.8b00003.
Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?.
Mouzat K, Chudinova A, Polge A, Kantar J, Camu W, Raoul C
Int J Mol Sci. 2019; 20(16).
PMID: 31398791
PMC: 6720493.
DOI: 10.3390/ijms20163858.
Beyond the Foam Cell: The Role of LXRs in Preventing Atherogenesis.
Rasheed A, Cummins C
Int J Mol Sci. 2018; 19(8).
PMID: 30087224
PMC: 6121590.
DOI: 10.3390/ijms19082307.
Liver X receptors as potential targets for cancer therapeutics.
Ju X, Huang P, Chen M, Wang Q
Oncol Lett. 2017; 14(6):7676-7680.
PMID: 29250170
PMC: 5727639.
DOI: 10.3892/ol.2017.7259.
From Classical Toxicology to Tox21: Some Critical Conceptual and Technological Advances in the Molecular Understanding of the Toxic Response Beginning From the Last Quarter of the 20th Century.
Choudhuri S, Patton G, Chanderbhan R, Mattia A, Klaassen C
Toxicol Sci. 2017; 161(1):5-22.
PMID: 28973688
PMC: 5837539.
DOI: 10.1093/toxsci/kfx186.
Liver X receptor activation promotes differentiation of regulatory T cells.
Herold M, Breuer J, Hucke S, Knolle P, Schwab N, Wiendl H
PLoS One. 2017; 12(9):e0184985.
PMID: 28926619
PMC: 5604992.
DOI: 10.1371/journal.pone.0184985.
Targeting nuclear receptors for the treatment of fatty liver disease.
Tanaka N, Aoyama T, Kimura S, Gonzalez F
Pharmacol Ther. 2017; 179:142-157.
PMID: 28546081
PMC: 6659998.
DOI: 10.1016/j.pharmthera.2017.05.011.
Ligands of Therapeutic Utility for the Liver X Receptors.
Komati R, Spadoni D, Zheng S, Sridhar J, Riley K, Wang G
Molecules. 2017; 22(1).
PMID: 28067791
PMC: 5373669.
DOI: 10.3390/molecules22010088.
Liver X receptors: from cholesterol regulation to neuroprotection-a new barrier against neurodegeneration in amyotrophic lateral sclerosis?.
Mouzat K, Raoul C, Polge A, Kantar J, Camu W, Lumbroso S
Cell Mol Life Sci. 2016; 73(20):3801-8.
PMID: 27510420
PMC: 11108529.
DOI: 10.1007/s00018-016-2330-y.
The LXR ligand GW3965 inhibits Newcastle disease virus infection by affecting cholesterol homeostasis.
Sheng X, Sun Y, Zhan Y, Qu Y, Wang H, Luo M
Arch Virol. 2016; 161(9):2491-501.
PMID: 27357231
PMC: 7087268.
DOI: 10.1007/s00705-016-2950-4.
Nuclear receptors and nonalcoholic fatty liver disease.
Cave M, Clair H, Hardesty J, Falkner K, Feng W, Clark B
Biochim Biophys Acta. 2016; 1859(9):1083-1099.
PMID: 26962021
PMC: 5149456.
DOI: 10.1016/j.bbagrm.2016.03.002.
Targeting liver X receptors in cancer therapeutics.
Lin C, Gustafsson J
Nat Rev Cancer. 2015; 15(4):216-24.
PMID: 25786697
DOI: 10.1038/nrc3912.